Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, spotlights key breast oncology updates from ESMO25.
4.5% iDFS benefit with ribo now (was 2.7% at 3 yrs).
Notably, N0 when selected for other risk characteristics, with just as much benefit.”
“Prof. Johnston presents OS for monarchE
Median f/u 6.3 yrs (all patients off Abemaciclib 4 plus years).
We now have an OS. 301 vs. 360 deaths – survival 1.8% 7 yrs (was 1% at 5, 1.3% at 6).
Still more alive with metastatic dz in ET alone.
iDFS 6.5% now.”
“ddAC-T + low dose Pembrolizumab (1/10th standard dose) improves pCR among the extremely high-risk group of TNBC (more than 80% node plus).
13.3% improvement in pCR.
Almost 10% hypothyroidism RDI, delayed, and completion of tx all equal.”
“POSITIVE outcomes at 71 mos in context of SOFT/TEXT.
Very reassuring that, at least in the short term, it isn’t detrimental to outcomes.
- 76% became pregnant.
- 82% resumed ET.
Remaining questions- long term? ER positive bcsm recurs for many, many years.”
“RIBOLARIS – high-risk estrogen receptor bcsm, 24 wks of Petrozole plus Ribociclib, then surgery. After surgery, treatment was guided by the Risk-of-Recurrence (ROR) score: those with a high ROR received Chemotherapy, while those with a low or intermediate ROR continued Endocrine Therapy plus Ribociclib.
- 40% node plus
- 52.6% patients were ROR low.
Not much use of ROR in the USA. It could be helpful for older, maybe chemotherapy-unfit.”
More posts featuring Erika Hamilton on OncoDaily.
